#Truvada

Previous studies of the association between tenofovir and COVID-19 outcomes in people with HIV have yielded mixed results.

A recent Japanese study found that this risk reduction was greater than that associated with the hep B vaccine.

The assurance arrives as the pharma giant cuts off most emergency access to remdesivir, a potential COVID-19 treatment.

HCV incidence in a Canadian study was lower than rates seen in some European countries.

Swiss researchers analyzed shifts in kidney function among those switching from the old form of the HIV medication to the new one.

Researchers believe that hepatitis C is spreading through sex from the HIV-positive population to those who don’t have HIV.

A look at the supply chain that results in very high costs for HIV and hepatitis C medications.

A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)

One percent of gay and bi men in a Dutch PrEP study contracted hepatitis C annually; of those cured, one in four were reinfected per year.

Additionally, in a recent study, having hep C mutations associated with resistance didn’t affect the outcome of treatment.

A recent study of Dutch clinicians found that they generally did a good job of preventing drug-drug interactions.

Highlights from HIV and hepatitis C research presented at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston

The once-daily regimen includes the integrase inhibitor bictegravir plus the contents of Descovy (emtricitabine/tenofovir alafenamide).

Largest-ever analysis of bone loss in the HIV population found that treating hep C, taking vitamin D and exercising might be preventive.

In four studies, this two-drug combination suppressed the virus as effectively as staying on a three-drug regimen.

Another initiative of the Elton John AIDS Foundation will focus on HIV and hep C in Eastern Europe and Central Asia.